MedAdvisor Limited (AU:AHE)
ASX:AHE
Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.02
<AU$0.01(10.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.17
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$12.75M
Enterprise ValueAU$17.17M
Total Cash (Recent Filing)AU$10.30M
Total Debt (Recent Filing)AU$17.40M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding637,676,800
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$110.67M
Bulls Say, Bears Say
Bulls Say
Pharmacy Platform & Consumer Medication AppMedAdvisor operates a pharmacy-focused software platform plus a consumer medication app that connects patients and pharmacies. This two-sided model creates recurring prescription workflows and engagement, generating durable network effects and stickiness as digital medication management adoption grows.
Improving Free Cash Flow GrowthAn 18.49% increase in free cash flow and FCF/net income at 1.0 indicate improving cash generation and conversion. Sustained FCF expansion enhances the company's ability to fund operations, product development or strategic initiatives without immediate equity raises, supporting medium-term resilience.
Positive Return On EquityA reported positive ROE suggests the business can generate returns from its equity base, implying operational efficiency or profitable unit economics at the margin. If maintained, this efficiency supports recovery potential and better capital allocation as revenues stabilize.
Bears Say
Sharp Revenue DeclineRevenue down ~39% year-over-year signals significant loss of demand or contracts and weak top-line traction. A shrinking revenue base reduces scale, pressures gross margins and customer economics, and limits the company’s ability to invest in product, sales, and partner relationships over the medium term.
Deep Unprofitable OperationsExtremely negative margins and persistent operating losses reflect an unsustainable cost structure relative to current revenue. Continued deep losses will erode capital, force dilution or increased borrowing, and constrain long-term investment in platform improvements unless structural revenue or cost changes occur.
Balance Sheet Solvency RiskNegative shareholders' equity and a -10.75 debt/equity metric indicate material solvency strain. This restricts financing options, increases refinancing risk, and may necessitate recapitalization or asset disposals, limiting strategic flexibility and raising long-term financial vulnerability.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.02 and its highest was AU$0.17 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$12.75M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 120 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.011.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,676,800 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$64.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
-137.16%
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
Options Prices
Currently, No data available
---